stockrowWest Pharmaceutical Services, Inc.
WST Healthcare Medical Instruments & Supplies
West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024.
- Revenue
- +8.69%
- EPS
- +56.7%
- Free cash flow
- +12.3%
- Total debt
- +0.10%
Quarter to September 2026, against a year earlier
Follow WST
Alert me
West Pharmaceutical Services, Inc. (WST) EBITDA
West Pharmaceutical Services, Inc.'s EBITDA for fiscal 2025 was $756.3M, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $964.5M. Over the past ten years it has ranged from $218.5M (fiscal 2015) to $874.6M (fiscal 2021); the current reading is higher than 73% of that period. West Pharmaceutical Services, Inc. ranks 8th of 47 Medical Instruments & Supplies companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $756.3M | 4.27% |
| FY2024 | $725.3M | (10.82%) |
| FY2023 | $813.3M | (4.83%) |
| FY2022 | $854.6M | (2.29%) |
| FY2021 | $874.6M | 69.50% |
| FY2020 | $516.0M | 29.00% |
| FY2019 | $400.0M | 16.04% |
| FY2018 | $344.7M | 6.88% |
| FY2017 | $322.5M | 12.80% |
| FY2016 | $285.9M | 30.85% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $313.3M | 39.06% |
| Jun 2026 | $225.3M | 1.35% |
| Mar 2026 | $222.3M | 9.18% |
| Dec 2025 | $203.6M | (3.32%) |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| MDLN Medline Inc. compare | $10.0B |
| BDX Becton, Dickinson and Company compare | $4.8B |
| ALC Alcon compare | $2.7B |
| SOLV Solventum Corporation compare | $2.6B |
| RMD ResMed Inc. compare | $2.1B |
| BAX Baxter International Inc. compare | $1.5B |
| WST West Pharmaceutical Services, Inc. | $964.5M |
| COO The Cooper Companies, Inc. compare | $928.2M |
| ALGN Align Technology, Inc. compare | $802.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on WST
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement